Elicera Therapeutics AB - Asset Resilience Ratio

Latest as of December 2022: 0.00%

Elicera Therapeutics AB (ELIC) has an Asset Resilience Ratio of 0.00% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Elicera Therapeutics AB (ELIC) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

Skr17.00

≈ $1.83 USD Cash + Short-term Investments

Total Assets

Skr46.31 Million

≈ $4.98 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2022)

This chart shows how Elicera Therapeutics AB's Asset Resilience Ratio has changed over time. See Elicera Therapeutics AB shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Elicera Therapeutics AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ELIC market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr0.00	0%
Short-term Investments	Skr17.00	0.0%
Total Liquid Assets	Skr17.00	0.00%

Asset Resilience Insights

Limited Liquidity: Elicera Therapeutics AB maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Elicera Therapeutics AB Industry Peers by Asset Resilience Ratio

Compare Elicera Therapeutics AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Argen-X F:1AE	Biotechnology	25.67%
Tubize-Fin BR:TUB	Biotechnology	0.05%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
Dashenlin Pharm Grp Co Ltd SHG:603233	Biotechnology	0.02%
Staidson Beijing Biopharma SHE:300204	Biotechnology	7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	41.25%
Ardelyx Inc NASDAQ:ARDX	Biotechnology	41.14%
Xiangxue Pharmaceutical SHE:300147	Biotechnology	0.05%

Annual Asset Resilience Ratio for Elicera Therapeutics AB (2022–2022)

The table below shows the annual Asset Resilience Ratio data for Elicera Therapeutics AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	0.00%	Skr17.00 ≈ $1.83	Skr46.31 Million ≈ $4.98 Million	--

pp = percentage points

About Elicera Therapeutics AB

ST:ELIC Sweden Biotechnology

Market Cap

$17.45 Million

Skr162.11 Million SEK

Market Cap Rank

#25440 Global

#524 in Sweden

Share Price

Skr3.34

Change (1 day)

+5.70%

52-Week Range

Skr3.13 - Skr7.90

All Time High

Skr8.56